Trinity Biotech Secures $5 Million Funding and Restructures Debt to Advance Continuous Glucose Monitoring Technology

Trinity Biotech查看公司主页 plc announced on December 23, 2025, that it has entered into a series of financial agreements with funds managed by Perceptive Advisors (搜索)搜索该词条 designed to strengthen the company's capital structure and support its diabetes management and diagnostic technology development programs. The commercial-stage biotechnology company secured $5 million in new term-loan proceeds and established mechanisms to potentially convert up to $60 million of existing debt into equity.

Financial Restructuring Details

The agreements include a Second Amendment to Trinity Biotech查看公司主页's Sixth Amended and Restated Credit Agreement, which provides $5 million of additional term-loan funding and extends the credit agreement maturity to January 15, 2027. A key component of the restructuring is the issuance of a new Convertible Promissory Note that allows Perceptive to convert up to $60 million of existing term-loan debt into the company's American Depositary Shares at the greater of 97% of the Volume Weighted Average Price at the time of conversion or a floor price of $1.03.

The company also established equity settlement mechanisms for milestone payments and contingent acquisition consideration related to its continuous glucose monitoring assets. Perceptive can satisfy a $5 million milestone payment obligation through optional conversion into ADSs under the same pricing terms. Additionally, up to $15 million of contingent acquisition consideration will be terminated in exchange for a $7.5 million payment that is also convertible into ADSs at Perceptive's election.

All conversions are subject to a 9.9% beneficial ownership cap to maintain compliance with ownership limitations.

Strategic Focus on Diabetes Technology

The funding will support Trinity Biotech查看公司主页's continued investment in key strategic development pipeline initiatives, including the company's innovative continuous glucose monitoring solution, CGM+ (搜索)搜索该药品. Trinity Biotech recently entered the wearable biosensor industry through the acquisition of biosensor assets from Waveform Technologies Inc (搜索)搜索该词条. and intends to develop a range of biosensor devices and related services, starting with continuous glucose monitoring products.

John Gillard, Trinity Biotech查看公司主页 CEO, stated: "We believe these developments place Trinity Biotech in a stronger strategic position to accelerate its innovation agenda, advancing our continuous glucose monitoring solution and other priority pipeline projects. The increased financial capacity and improved operational flexibility created by these arrangements enable us to focus on delivering impactful technologies in diabetes management and diagnostics, supporting the company's growth trajectory and reinforcing the foundations for long-term shareholder value."

Company Background and Market Position

Trinity Biotech查看公司主页 operates as a commercial-stage biotechnology company focused on diabetes management solutions and human diagnostics, including wearable biosensors. The company develops, acquires, manufactures and markets diagnostic systems for both point-of-care and clinical laboratory segments. Its products are used to detect infectious diseases and quantify Haemoglobin A1c and other chemistry parameters in serum, plasma and whole blood.

The company sells directly in the United States and through a network of international distributors and strategic partners in over 75 countries worldwide. The agreements with Perceptive Advisors (搜索)搜索该词条 reflect a continued positive relationship between the parties and underscore Perceptive's support for Trinity Biotech查看公司主页's strategy and operating momentum.